Moreover, targeted therapies have recently made their way in gastric cancer with the approval of trastuzumab for the treatment of HER-2 positive metastatic gastric cancer [16] Anti-angiogenics (bevacizumab) and anti-EGFR agents (cetuximab) are also being studied in the adjuvant setting. This evidence concerns the gene ERBB2 and gastric cancer.